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Abstract
Background: Glioblastoma (GBM) is the most malignant nervous system tumor with an almost 100 % recurrence
rate. Thymopoietin (TMPO) has been demonstrated to be upregulated in various tumors, including lung cancer,
breast cancer, and so on, but its role in GBM has not been reported. This study was aimed to determine the role
of TMPO in GBM.
Methods: Publicly available Oncomine dataset analysis was used to explore the expression level of TMPO in GBM
specimens. Then the expression of TMPO was knocked down in GBM cells using lentiviral system, and the knockdown
efficacy was further validated by real-time quantitative PCR and western blot analysis. Furthermore, the effects of TMPO
silencing on GBM cell proliferation and apoptosis were examined by MTT, colony formation, and flow cytometry
analysis. Meanwhile, the expression of apoptotic markers caspase-3 and poly(ADP-ribose) polymerase (PARP) were
investigated by western blot analysis.
Results: This study observed that the expression of TMPO in GBM specimens was remarkably higher than that in
normal brain specimens. Moreover, knockdown of TMPO could significantly inhibit cell proliferation and arrest cell cycle
progression at the G2/M phase. It also found that TMPO knockdown promoted cell apoptosis by upregulation of the
cleavage of caspase-3 and PARP protein levels which are the markers of apoptosis.
Conclusions: The results suggested TMPO might be a novel therapeutic target for GBM.
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Background
Glioblastoma (GBM) (World Health Organization grade
IV astrocytoma) is the most frequent and most malignant
brain tumor. The standard therapy method for newly di-
agnosed GBM is surgery followed by radiotherapy plus
temozolomide chemotherapy [1]. But the GBM is still
along with a 100 % recurrence rate and about a 5 % 5-year
survival rate [2, 3]. Researchers are screening new drugs
for GBM treatment, such as bevacizumab, which is a hu-
manized monoclonal antibody against vascular endothelial
growth factor A (VEGF-A), but it cannot improve overall
survival in patients with GBM; the adverse events such as
increased symptom severity are more serious [4, 5]. So the
development of new therapeutic targets is essential for
GBM therapy.
Thymopoietin (TMPO) is also named as lamina-
associated polypeptide 2 (LAP2) and has six alternatively
spliced isoforms with different functions [6]. TMPO can
interact with lamins and BAF to regulate the organization
of the nuclear structure and the dynamics of the cell cycle
[7]. Recently, the role of TMPO in cancer biology has
been reported [8]. LAP2β is upregulated in the rapidly
proliferating cells of various hematological malignancies
but is normally expressed in the slowly proliferating cells
of chronic malignant hematological diseases [9]. LAP2β is
upregulated in digestive tract tumor tissues and cells; its
knockdown could inhibit migration, invasion, and metas-
tasis but has no effect on cell proliferation. In pancreatic
cancer cells, knockdown of LAP2β not only inhibits cell
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proliferation but also suppresses migration, invasion, and
metastasis [10].
However, the role of TMPO in GBM has not been re-
ported until now. In this study, short hairpin RNA
(shRNA) for TMPO was used to knock down TMPO in
GBM cells and the MTT assay and colony formation
assay were used to determine the effect of TMPO on
cell proliferation. Finally, the approach of TMPO that
regulated cell proliferation, cell cycle progression, or
apoptosis was determined. In addition, the knockdown
of TMPO reduced the cell proliferation rate caused by
promoting apoptosis.
Methods
Data mining and Oncomine analysis
A series of microarray datasets for glioblastoma were
retrieved from the public Oncomine cancer microarray
database (www.oncomine.org) to investigate TMPO ex-
pression in glioblastoma [11]. Differential expressions
of TMPO between glioblastoma and normal tissues
were retrieved from seven different databases, including
French Brain [12], Liang Brain [13], Murat Brain [14],
TCGA Brain (The Cancer Genome Atlas-Glioblastoma
Multiforme Gene Expression Data, http://tcga-data.nci.
nih.gov/tcga/), Shai Brain [15], Sun Brain [16], and
Pomeroy Brain [17]. The TMPO gene expression in glio-
blastoma was compared with normal brain tissues accord-
ing to the previously described [18].
Cell lines and culture
GBM cells including U251 and U87 and human embry-
onic kidney cell line 293T were purchased from the Cell
Bank of Chinese of Science (Shanghai, China). U251 was
cultured in DMEM (SH30243.01B, HyClone, USA) sup-
plemented with 10 % fetal bovine serum (FBS, S1810, Bio-
west, Spain). U87 was cultured in EMEM (SH30024.01B,
HyClone, USA) supplemented with FBS, 1 % PEP, and 1 %
NEAA. 293T cells which were used to package lentivirus
were cultured in DMEM supplemented with 10 % FBS.
All cells were maintained in a humidified atmosphere at
37 °C with 5 % CO2.
Vector construction and virus infection
The sequences (S1: 5′-GCACAGATTCTTAGCTCAGAT-
3′, S2: 5′-CTTGTGAAATACGGAGTGAAT-3′) were
used as the target sequence to downregulate the TMPO
(NM_003276.2) level, and shRNA oligos for TMPO were
cloned into the pFH-L lentiviral vector (Hollybio, Shanghai,
China) which carried green fluorescent protein (GFP) and
were indicated as TMPO-shRNA and TMPO-shRNA(S2).
The sequence (5′-TTCTCCGAACGTGTCACGT-3′) was
used as a scramble control and cloned into the pFH-L vec-
tor (Con-shRNA). Then the shRNA plasmid and two
pHelper plasmids pVSVG-I and pCMVΔR8.92 were co-
transfected into 293T cells using the calcium phosphate
transfection protocol. The viral supernatants were col-
lected and filtered at 48 h after transfection. For lentivirus
infection, U251 and U87 cells were seeded in six-well
plates at a density of 7 × 104 cells/well and 5 × 104 cells/
well, respectively. Subsequently, the lentiviruses containing
TMPO-shRNA, TMPO-shRNA(S2), or Con-shRNA were
transduced into U251 and U87 cells at 10 and 8 MOI
(multiplicity of infection), respectively. After a 72-h infec-
tion, the infection efficiency was determined by observing
the GFP expression under a fluorescence microscope.
RNA extraction and real-time quantitative PCR
Total RNA was extracted using RNAiso Plus reagent
(Takara, Japan) according to the manufacturer’s instruc-
tions and synthesized into complementary DNA
(cDNA) using HiScript 1st Strand cDNA Synthesis Kit
(Vazyme, China). TMPO expression was quantified
using HiScript® Q RT SuperMix for qPCR (Vazyme,
China) in a BioRad Connet Real-Time PCR platform
and performed in triplicates. Actin was used as an en-
dogenous control for normalization. The relative ex-
pression of TMPO was calculated as using the 2−ΔΔCt
method [19]. Ct was the threshold cycle of each transcript.
The real-time quantitative PCR primers were shown as
follows: TMPO: forward, 5′-TGCTCGCCTCCTGCCTG
TAG-3′ and reverse, 5′-GACACAAAGCCAAGCCAGA
CC-3′; Actin: forward, 5′-GTGGACATCCGCAAAGAC-
3′ and reverse, 5′-AAAGGGTGTAACGCAACTA-3′.
Western blot
Total protein was extracted from cells using RIPA buf-
fer (50 mM Tris-HCl, at pH 8.0, 150 mM NaCl, 5 mM
EDTA, 0.1 % SDS, and 1 % NP-40). The protein sam-
ples (30 μg/well) were loaded and separated by 10 %
SDS-polyacrylamide gel electrophoresis (PAGE). Western
blot was performed according to the previous report [20].
Anti-TMPO (1:1000, 14651-1-AP, Proteintech, USA),
poly(ADP-ribose) polymerase (PARP;1:1000, #9542, Cell
Signaling Technology, USA), and caspase-3 (1:500, Cell
Signaling Technology, USA) antibodies were used. An
anti-GAPDH antibody (1:500000, 10494-1-AP, Proteintech,
USA) was used as the loading control. The secondary anti-
body used was horseradish peroxidase (HRP)-conjugated
goat anti-rabbit antibody (1:5000, SC-2054, Santa Cruz,
USA).
Cell proliferation analysis by MTT
After lentivirus infection for 72 h, a total density of
2500 cells/well for U251 cells or 3000 cells/well for
U87 cells were reseeded in a 96-well plate. The cell via-
bility was determined at five different timing points
(days 1, 2, 3, 4, and 5) using the MTT assay. Briefly,
20 μl of MTT (Sigma, USA) solution was added to the
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wells and incubated for 4 h at 37 °C. Then 100 μl acidic
isopropanol solution (10 % SDS, 5 % isopropanol, and
0.0 1 mol/l HCl) was added and incubated overnight to
solubilize the formazan. The optical density (OD) value
was measured at 570 nm using a microplate reader
(Epoch, BioTek, USA). All experiments were performed
in triplicates.
Colony formation assay
Colony formation assay was carried out according to the
previous report [21]. Briefly, U251 cells stably trans-
duced lentivirus were reseeded on six-well plates and
cultured for 12 days at a density of 600 cells/well. Then
colonies were fixed using 4 % paraformaldehyde for
5 min and then stained with 1 % crystal violet for 30 s.
The cells were photographed, and the number of col-
onies was counted.
Flow cytometric analysis of the cell cycle
After lentivirus infection for 5 days, a total density of
80,000 cells/dish for U251 cells were reseeded in 6-cm
dishes and continued to culture for 72 h. Then cells were
collected, washed with pre-cooling PBS, and fixed with
cooling 70 % ethanol overnight at 4 °C. After washing
twice with pre-cooling PBS, the cells were resuspended
and incubated in 500 μl PBS containing 50 μg/ml propi-
dium iodide solution (PI) and 100 μg/ml RNase for
30 min at room temperature. Finally, the cells were ana-
lyzed on a FACS Calibur cytometer (BD, USA). Data were
analyzed using CellQuest software.
Apoptosis analysis
Apoptosis analysis was performed using the Annexin V-
APC/7-AAD apoptosis kit (KeyGEN Biotech, Nanjing,
China) according to the manufacturer’s instructions. Cells
were analyzed on a FACS Calibur cytometer (BD, USA).
Data were analyzed using CellQuest software.
Statistical analysis
Statistical analysis was performed using SPSS 19 (SPSS
Inc., USA). Results are shown as the mean ± standard
deviation (STDEV) for at least three repeated individual
experiments for each group. Statistical differences were
determined using Student’s t test for independent sam-
ples. p < 0.05 was considered statistically significant.
Results
TMPO mRNA expression was elevated in glioblastoma
To analyze the expression level of TMPO in GBM, the
publicly available Oncomine cancer microarray database
was excavated. As shown in Fig. 1a, the French Brain data-
set showed that TMPO expression is significantly elevated
in oligodendroglioma (n = 23, p = 5.62E−4) compared with
the normal tissues. Comparing with normal brain tissues,
TMPO expression in glioblastoma tissues is much higher
as shown in three different microarray datasets including
the Liang Brain dataset (n = 30, p = 0.015), the Murat
Brain dataset (n = 80, p = 0.010), and the TCGA Brain
dataset (n = 542, p = 1.29E−6) (Fig. 1b–d). Also, TMPO
expression was significantly increased in glioblastoma
tissues (n = 27, p = 0.002) and oligodendroglioma tissues
(n = 3, p = 0.043) in the Shai Brain dataset (Fig. 1e).
Fig. 1 Upregulation of TMPO mRNA in GBM was revealed by Oncomine database. The expression of the TMPO gene was extracted and analyzed
from a the French Brain dataset, b the Liang Brain dataset, c the Murat Brain dataset, d the TCGA Brain dataset, e the Shai Brain dataset, f the Sun
Brain dataset, and g the Pomeroy Brain dataset shown as scatterplots
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Furthermore, the Sun Brain dataset revealed that
TMPO was upregulated in glioblastoma tissues (n = 81,
p = 2.22E−8) and oligodendroglioma tissues (n = 50, p =
2.25E−5) compared with normal brain tissues (Fig. 1f).
The results of the Pomeroy Brain dataset were similar to
the abovementioned results that the expression level of
TMPO was also significantly higher in malignant glioma
(n = 10, p = 0.015) than that in the normal tissues (Fig. 1g).
These data suggested that TMPO might play an under-
lying carcinogenesis in glioblastoma.
TMPO-shRNA could knock down TMPO effectively
To determine the role of TMPO in GBM, TMPO-
shRNA was used to knock down TMPO in U251 and
U87. Quantitative real-time PCR revealed that the
knockdown efficiency of TMPO in the messenger RNA
(mRNA) level was about 60 % in U251 cells and up to
90 % in U87 cells (Fig. 2a). As shown in Fig. 2b, TMPO
protein levels were reduced in both U251 and U87 cells
infected with TMPO-shRNA by western blot assay.
Moreover, western blot analysis also confirmed that the
TMPO protein level in the TMPO-shRNA(S2) group
was significantly decreased compared with that in the
Con-shRNA group in U251 cells (Fig. 2c). These results
suggested TMPO-shRNA constructed successfully signifi-
cantly suppressed TMPO expression both at the mRNA
and protein levels.
Knockdown of TMPO inhibited cell proliferation
To determine whether TMPO affects GBM cell prolifer-
ative abilities, MTT and colony formation assays were
carried out. As shown in Fig. 3a, b, the growth rate of
the TMPO-shRNA group was significantly suppressed
by 37.3 and 63.5 % compared to the Con-shRNA group
on day 5 in U251 (OD value, 1.66 ± 0.04 vs. 2.65 ± 0.08,
p < 0.001) and U87 (OD value, 0.77 ± 0.03 vs. 2.10 ± 0.08,
p < 0.001) cells, respectively. Similarly, compared with
the Con-shRNA group, the proliferative ability on day 5
in the TMPO-shRNA(S2) group was also observably
inhibited by 58.9 % in the U251 cells (OD value, 2.58 ±
0.16 vs. 6.26 ± 0.30, p < 0.001, Fig. 3c). Moreover, the col-
ony formation ability of U251 cells infected with the
TMPO-shRNA or the TMPO-shRNA(S2) group was fur-
ther explored, and the size and number of the colony were
both smaller in both the TMPO-shRNA and TMPO-
shRNA(S2) groups than those in the Con-shRNA group
(Fig. 3d). In comparison with the Con-shRNA group, the
numbers of colonies were markedly lower in the TMPO-
shRNA group (28 ± 6 vs. 128 ± 17, p < 0.01) and the
TMPO-shRNA(S2) group (4 ± 1 vs. 133 ± 5, p < 0.001) in
the U251 cells (Fig. 3e). These results suggested that
knockdown of TMPO could inhibit the proliferation and
colony formation abilities of GBM cells.
Knockdown of TMPO arrested the cell cycle at the G2/M
phase
The approach of TMPO that regulated cell proliferation
was further demonstrated. Cell cycle analysis was per-
formed by flow cytometry in U251 cells after TMPO
knockdown (Fig. 4a, d). As shown in Fig. 4b, the knock-
down of TMPO in U251 cells decreased the population
of the G0/G1 phase (51.2 ± 0.3 % vs. 61.8 ± 0.1 %, p <
0.001) and increased the population of the G2/M phase
(32.3 ± 0.7 % vs. 21.1 ± 0.3 %, p < 0.001) in comparison
with the Con-shRNA group. Similar to the results of the
TMPO-shRNA group in the U251 cells, a visible de-
crease in the cell proportion in the G0/G1 phase (49.5 ±
1.4 % vs. 63.5 ± 0.9 %, p < 0.001) was observed but an in-
crease in the G2/M phase (18.9 ± 2.1 % vs. 10.4 ± 0.5 %,
p < 0.05) in the TMPO-shRNA(S2) group compared with
the Con-shRNA group (Fig. 4d). But the S phase popula-
tion did not change in both the TMPO-shRNA and
TMPO-shRNA(S2) groups. This suggested the cell cycle
was arrested at the G2/M phase by TMPO knockdown.
Furthermore, the apoptotic population of U251 cells in
the sub-G1 phase was significantly increased in both the
Fig. 2 Knockdown efficiency of TMPO by lentivirus infection in the GBM cells. a Quantitative real-time PCR analysis of TMPO knockdown efficiency
in U251 and U87 cells. The mRNA expression of TMPO was significantly suppressed when the cells were infected with TMPO-shRNA. b Western
blot analysis validated TMPO-shRNA effectively downregulated the protein level of TMPO in U251 and U87 cells. c Western blot analysis confirmed
TMPO-shRNA(S2) effectively decreased the protein expression of TMPO in U251 cells. **p < 0.01; scale bars, 10 μm
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TMPO-shRNA (1.9 ± 0.1 % vs. 0.3 ± 0.0 %, p < 0.001) and
TMPO-shRNA(S2) groups (24.2 ± 0.8 % vs. 7.0 ± 2.0 %,
p < 0.01) in comparison with the Con-shRNA groups
(Fig. 4c, f ). These results suggested that TMPO knock-
down could inhibit GBM cell growth via inducing cell
cycle arrest.
Knockdown of TMPO promoted cell apoptosis
The effect of TMPO silencing on cell apoptosis was fur-
ther confirmed using an apoptosis detection kit, and it
was found that knockdown of TMPO in U251 cells in-
creased early apoptotic cells (Annexin V+/7-AAD−)
from 2.7 ± 0.2 % to 62.2 ± 0.5 % (p < 0.001) and late
apoptotic cells (Annexin V+/7-AAD+) from 3.1 ± 0.0 %
to 24.82 ± 0.5 % (p < 0.001) and increased nearly 15-fold
the total cell apoptotic population of the TMPO-shRNA
group compared to the Con-shRNA group (p < 0.001)
(Fig. 5a, c). Moreover, the cell percentage was more in the
early (32.4 ± 2.1 % vs. 1.4 ± 0.4 %, p < 0.01) and late (14.1
± 1.7 % vs. 0.0 ± 0.0 %, p < 0.01) apoptosis in the TMPO-
shRNA(S2) group than in the Con-shRNA group, and
there was an over-32-fold increase in the total cell
apoptotic population of the TMPO-shRNA(S2) group
compared to the Con-shRNA group (p < 0.001) (Fig. 5b, d).
The results revealed that TMPO silencing produced a
strong cell apoptotic effect in GBM cells.
To explore the role of related cell apoptotic mole-
cules in the knockdown of TMPO-induced cell apop-
tosis, the effect of TMPO silencing on two classical cell
apoptotic molecules caspase-3 and PARP was examined
by western blot assay. Caspase-3 is a key executioner of
apoptosis and can break many key proteins for apoptosis
such as poly(ADP-ribose) polymerase (PARP) [22, 23].
Cleavage of PARP is a marker for cell apoptosis [24]. As
shown in Fig. 5e, the expressions of cleaved caspase-3 and
cleaved PARP were remarkably increased once TMPO
was knocked down. Taken together, the results suggested
that TMPO knockdown in U251 cells promoted cell apop-
tosis due to the upregulation of cleaved caspase-3 and
PARP expression.
Discussion
In the present study, the role of TMPO in GBM was in-
vestigated and it was found that TMPO was overexpressed
Fig. 3 Downregulation of TMPO inhibited the proliferation of GBM cells. a, b Cell proliferation in U251 and U87 cells after TMPO-shRNA infection was
determined by MTT assay, respectively. c The proliferation of U251 cells was examined after TMPO-shRNA(S2) infection by MTT assay. d Representative
microscopic images of colonies in TMPO-shRNA- or TMPO-shRNA(S2)-infected U251 cells were stained by crystal violet. e Statistical analysis of the
number of colonies. **p < 0.01, ***p < 0.001; scale bars, 25 μm
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in GBM tissues. By knockdown of the TMPO expression,
cell proliferation was suppressed by the MTT and colony
formation assays. In addition, when TMPO was downreg-
ulated, the percentage of the S phase population did not
change, the percentage of G0/G1 was significantly re-
duced, and the percentage of G2/M was significantly in-
creased, which suggested that the cell cycle was arrested
at the G2/M phase after treatment with TMPO-shRNA.
This might be because TMPO regulates nuclear assembly
in the mitosis; knockdown of TMPO reduced the rate of
nuclear assembly [25].
It has been demonstrated that there is a close relation
between cell cycle arrest and DNA damage response
[26, 27]. Accumulation of the G2/M phase population
is prominently related with apoptosis [28]. The finding
that knockdown of TMPO induced cell cycle arrest at the
G2/M phase prompted us to examine whether apoptosis
occurred in U251 cells. As expected, knockdown of TMPO
Fig. 4 Downregulation of TMPO arrested the cell cycle of U251 cells. a, d The cell cycle distribution determined by flow cytometer. b, e Statistical
analysis of the cell cycle in the U251 cells with TMPO knockdown. c, f The respective proportion of sub-G1 phase cells. *p < 0.05, **p < 0.01, ***p < 0.001
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significantly elevated the percentage of cells in early apop-
totic and late apoptotic stages. Western blot further sug-
gested knockdown of TMPO increased the cleavage of
caspase-3 and PARP expression. Caspase activation plays a
critical role in apoptosis and is divided into two types: initi-
ator caspases (caspases-2, 8, 9, 10) and effector caspases
(caspases-3, 6, 7). Both the intrinsic pathway and the ex-
trinsic pathway can activate initiator caspases; initiator cas-
pases then cleave and activate effector caspases. Effector
caspases subsequently cleave substrate proteins which are
essential for cell survival, such as PARP [29, 30].
PARP is proteolysed by caspase-3 into two fragments,
a 24-kDa DNA-binding fragment and an 89-kDa cata-
lytic fragment [24]. The cleavage of PARP is critical for
apoptosis because it can prevent apoptosis induced by
energy depletion and cell survival induced by DNA re-
pair [31, 32]. The results further confirmed that TMPO
knockdown promoted apoptosis. The new targets for
GBM therapy are critical; inhibition of TMPO could in-
duce apoptosis, suggesting it might be a novel target for
GBM treatment.
Conclusions
This study found TMPO is significantly upregulated in
GBM tissues. Functional analysis indicated that knock-
down of TMPO suppressed GBM cell proliferation by
inducing cell cycle arrest and apoptosis. Although the
precise mechanisms are not yet fully understood, this
finding suggests that TMPO might play an important
role in regulating the proliferation of glioma cells and
serve as a new target for GBM treatment.
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